Dare Bioscience

Dare Bioscience Debt/EBITDA

The Total Debt to EBITDA Ratio of Dare Bioscience (DARE) as of Oct 31, 2026 is -0.20. In the previous year, Total Debt to EBITDA Ratio was -0.06 — a change of 252.72% (lower).

Debt/EBITDA

-0.20

YoY

252.72%

Last updated:

Total Debt to EBITDA Ratio of Dare Bioscience is 2025 -0.20 . Total Debt to EBITDA Ratio of Dare Bioscience was 2024 -0.06 . It decreases by 252.72% lower compared to the previous year.

The Dare Bioscience Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2017
0.00 USD
Jan 1, 2019
-0.06 USD
Jan 1, 2020
-0.03 USD
Jan 1, 2021
-0.01 USD
Jan 1, 2022
-0.02 USD
Jan 1, 2023
-0.05 USD
Jan 1, 2024
-0.06 USD
Jan 1, 2025
-0.20 USD
The Dare Bioscience Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.20+252.72%
-0.06+22.40%
-0.05+191.51%
-0.02+124.87%
-0.01-74.93%
-0.03-50.50%
-0.06—
0.00-100.00%
-0.35-36.89%
-0.55+254.92%
-0.15—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dare Bioscience Stock analysis

What does Dare Bioscience do? Daré Bioscience, Inc. develops and commercializes pharmaceutical products in women's reproductive health, focusing on non-hormonal contraceptive solutions. Its lead product, Ovaprene, is a clinical stage intravaginal ring designed to provide multi-week protection without intervention during intercourse. The ring features a permeable mesh barrier and localized spermiostatic agent delivery, combining barrier and spermicidal mechanisms to achieve efficacy comparable to diaphragms and short-acting hormonal methods like oral pills and vaginal rings. The company targets women seeking non-hormonal contraceptive options, with Ovaprene positioned as an alternative to existing hormonal products and barrier methods. The firm generates revenue through the development and commercialization of Ovaprene, aiming to address unmet needs in women's reproductive health. Ovaprene is designed to offer a non-hormonal, user-friendly alternative to traditional hormonal contraceptives, appealing to consumers who prefer avoiding hormonal side effects. The company's focus on clinical development and product commercialization aligns with the market demand for innovative, non-hormonal contraceptive options in women's health. Dare Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dare Bioscience stock

Total Debt to EBITDA Ratio of Dare Bioscience is -0.20 in 2025.

Total Debt to EBITDA Ratio of Dare Bioscience changed from -0.06 to -0.20, representing a 252.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Dare Bioscience since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Dare Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Dare Bioscience

All Key Metrics — Dare Bioscience